An Observational Registry of Abatacept in Patients with JIA
Research type
Research Study
Full title
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis
IRAS ID
166596
Contact name
Athimalaipet Ramanan
Contact email
Sponsor organisation
Bristol-Myers Squibb
Clinicaltrials.gov Identifier
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
The short-term safety of abatacept when used in juvenile idiopathic arthritis (JIA) has been previously demonstrated; however, the long-term safety of abatacept has not been well studied. Thus, as part of regulatory requirements, an international registry with long-term follow-up will be established to characterize and evaluate the safety of abatacept.
REC name
North West - Preston Research Ethics Committee
REC reference
15/NW/0256
Date of REC Opinion
7 Apr 2015
REC opinion
Unfavourable Opinion